Takeda Pharmaceutical (NYSE:TAK) Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.
Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations. The company concentrates on several core therapeutic areas, including oncology, gastroenterology, neuroscience, rare diseases and plasma-derived therapies, and maintains an active development pipeline aimed at advancing innovative treatments. In addition to internally discovered assets, Takeda has expanded its capabilities and portfolio through strategic acquisitions that broaden its rare-disease and specialty-care offerings.
Operating globally, Takeda serves patients and healthcare systems across North America, Europe, Asia and other regions through a network of research sites, manufacturing facilities and commercial offices. Leadership is headed by Christophe Weber, who serves as president and chief executive officer and has overseen the company’s transformation into a global specialty biopharma organization. Takeda emphasizes long-term investment in research and development, strategic collaborations, and patient-focused initiatives as central elements of its corporate strategy.
